Old drug, new hope? ibrutinib tackles tough brain cancer
NCT ID NCT05782374
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study reviews medical records of 36 adults with relapsed or refractory primary central nervous system lymphoma (PCNSL) who were treated with ibrutinib alone or with R-CHOP chemo. The goal is to see how many patients respond to treatment. PCNSL is a rare and aggressive brain lymphoma, and this research aims to find better options for those who have failed initial therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ibrutinib
- What this could lead to
- If this works, it could offer a treatment option for people with relapsed PCNSL, a rare and aggressive brain lymphoma.
- What could go wrong
- This is a small, retrospective study with only 36 participants, so results may not apply to everyone. Ibrutinib can cause side effects like bleeding or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PCNSL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ospedale San Raffaele
Milan, Italy, 20132, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.